JP2022518906A5 - - Google Patents

Info

Publication number
JP2022518906A5
JP2022518906A5 JP2021542541A JP2021542541A JP2022518906A5 JP 2022518906 A5 JP2022518906 A5 JP 2022518906A5 JP 2021542541 A JP2021542541 A JP 2021542541A JP 2021542541 A JP2021542541 A JP 2021542541A JP 2022518906 A5 JP2022518906 A5 JP 2022518906A5
Authority
JP
Japan
Prior art keywords
approximately
crystalline
monoedisylate
diffraction pattern
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021542541A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022518906A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/015370 external-priority patent/WO2020159959A1/en
Publication of JP2022518906A publication Critical patent/JP2022518906A/ja
Publication of JP2022518906A5 publication Critical patent/JP2022518906A5/ja
Priority to JP2023188791A priority Critical patent/JP2024039020A/ja
Priority to JP2025114666A priority patent/JP2025165933A/ja
Pending legal-status Critical Current

Links

JP2021542541A 2019-01-29 2020-01-28 サルカルディン塩 Pending JP2022518906A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023188791A JP2024039020A (ja) 2019-01-29 2023-11-02 サルカルディン塩
JP2025114666A JP2025165933A (ja) 2019-01-29 2025-07-07 サルカルディン塩

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962798467P 2019-01-29 2019-01-29
US62/798,467 2019-01-29
US202062959687P 2020-01-10 2020-01-10
US62/959,687 2020-01-10
PCT/US2020/015370 WO2020159959A1 (en) 2019-01-29 2020-01-28 Sulcardine salts

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023188791A Division JP2024039020A (ja) 2019-01-29 2023-11-02 サルカルディン塩

Publications (2)

Publication Number Publication Date
JP2022518906A JP2022518906A (ja) 2022-03-17
JP2022518906A5 true JP2022518906A5 (cg-RX-API-DMAC10.html) 2022-10-31

Family

ID=69724142

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021542541A Pending JP2022518906A (ja) 2019-01-29 2020-01-28 サルカルディン塩
JP2023188791A Pending JP2024039020A (ja) 2019-01-29 2023-11-02 サルカルディン塩
JP2025114666A Pending JP2025165933A (ja) 2019-01-29 2025-07-07 サルカルディン塩

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023188791A Pending JP2024039020A (ja) 2019-01-29 2023-11-02 サルカルディン塩
JP2025114666A Pending JP2025165933A (ja) 2019-01-29 2025-07-07 サルカルディン塩

Country Status (16)

Country Link
US (4) US11426382B2 (cg-RX-API-DMAC10.html)
EP (1) EP3917921A1 (cg-RX-API-DMAC10.html)
JP (3) JP2022518906A (cg-RX-API-DMAC10.html)
KR (2) KR102405199B1 (cg-RX-API-DMAC10.html)
CN (2) CN112638903B (cg-RX-API-DMAC10.html)
AU (1) AU2020216925B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021014640A8 (cg-RX-API-DMAC10.html)
CA (1) CA3128152A1 (cg-RX-API-DMAC10.html)
CL (1) CL2021001968A1 (cg-RX-API-DMAC10.html)
CO (1) CO2021011042A2 (cg-RX-API-DMAC10.html)
IL (1) IL285184B2 (cg-RX-API-DMAC10.html)
MX (2) MX2021009033A (cg-RX-API-DMAC10.html)
PH (1) PH12021551818A1 (cg-RX-API-DMAC10.html)
SG (1) SG11202108160YA (cg-RX-API-DMAC10.html)
WO (1) WO2020159959A1 (cg-RX-API-DMAC10.html)
ZA (2) ZA202105344B (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020123824A1 (en) 2018-12-13 2020-06-18 Huya Bioscience International, Llc Sulcardine administration for treatment of acute atrial fibrillation
KR102405199B1 (ko) * 2019-01-29 2022-06-02 후야 바이오사이언스 인터내셔널 엘엘씨 설카딘 염
US11813245B2 (en) * 2020-06-12 2023-11-14 Huyabio International, Llc Sulcardine administration for treatment of acute atrial fibrillation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1172908C (zh) * 1999-12-10 2004-10-27 中国科学院上海药物研究所 N-取代苄基或苯基芳香磺酰胺化合物及其用途
CN1299813C (zh) 2004-12-28 2007-02-14 华南理工大学 自动撕膜落料及多样性搅拌的机构和控制装置
CN1939298A (zh) * 2005-09-29 2007-04-04 中国科学院上海药物研究所 硫酸舒欣啶固体和靶向制剂及其制备方法
US8541464B2 (en) 2009-11-17 2013-09-24 HUYA Biosciences International LLC Treatment of atrial fibrillation
WO2011062903A2 (en) * 2009-11-17 2011-05-26 Elliott Gary T Slow infusion of sulcardine and its salts
MA41599A (fr) * 2015-02-26 2018-01-02 Array Biopharma Inc Formes cristallines d'un composé pyrrolopyridine
EP3302442B1 (en) 2015-06-03 2024-10-16 Triastek, Inc. Dosage forms and use thereof
AU2017261372B2 (en) 2016-05-05 2019-02-14 Triastek, Inc. Controlled release dosage form
AU2018212273B2 (en) 2017-01-26 2023-12-21 Triastek, Inc. Dosage forms of controlled release at specific gastrointestinal sites
US10370381B2 (en) * 2017-02-24 2019-08-06 Gilead Sciences, Inc. Inhibitors of bruton'S tyrosine kinase
WO2020123824A1 (en) 2018-12-13 2020-06-18 Huya Bioscience International, Llc Sulcardine administration for treatment of acute atrial fibrillation
KR102405199B1 (ko) * 2019-01-29 2022-06-02 후야 바이오사이언스 인터내셔널 엘엘씨 설카딘 염

Similar Documents

Publication Publication Date Title
JP2025165933A5 (cg-RX-API-DMAC10.html)
JP2022532790A5 (cg-RX-API-DMAC10.html)
JP2021020902A5 (cg-RX-API-DMAC10.html)
JP2025092508A5 (cg-RX-API-DMAC10.html)
JP2009537538A5 (cg-RX-API-DMAC10.html)
RU2598606C3 (ru) Кристаллическая тозилатная соль (8s,9r)-5-фтор-8-(4-фторфенил)-9-(1-метил-1н-1,2,4-триазол-5-ил)-8-9-дигидро-2н-пиридо[4,3,2-de]фталазин-3(7н)-она
IL214086A (en) Malt salt of n- {4 - {[7,6- bis (methyllaxy) quinoline-4-yl] oxy} phenyl) - n- (4-fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms for cancer treatment
EP2620145A3 (en) 2,5-dihydroxybenzene compounds for the treatment of of cancer of an organ
JP2022163049A5 (cg-RX-API-DMAC10.html)
JP2010514807A5 (cg-RX-API-DMAC10.html)
JP2006522006A5 (cg-RX-API-DMAC10.html)
JP2023109937A5 (cg-RX-API-DMAC10.html)
PE20081157A1 (es) Forma cristalina de hemifumarato de alisquireno
JP2014530818A5 (cg-RX-API-DMAC10.html)
JP2015522037A5 (cg-RX-API-DMAC10.html)
JP2023500060A5 (cg-RX-API-DMAC10.html)
JP2023533289A5 (cg-RX-API-DMAC10.html)
FI3365321T3 (fi) Solabegron-Zwitterioni ja sen käyttöjä
JP2019151627A5 (cg-RX-API-DMAC10.html)
JP2023524518A5 (cg-RX-API-DMAC10.html)
JP2011520991A5 (cg-RX-API-DMAC10.html)
IL266097B (en) Mono-orotate acid addition salt of r(–5–)–e(–2–)pyrrolidine––3ylvinyl)pyrimidine
KR20180059390A (ko) 근육통과 관련된 상태의 치료를 위한 배합물
JP2025527471A5 (cg-RX-API-DMAC10.html)
CA2493326A1 (en) Hydrates of a salt of (s)-pantoprazole